Cabaletta Bio (Cabaletta Bio) Price-to-Operating-Cash-Flow

: (As of Today)

View and export this data going back to 2019. Start your Free Trial

As of today (2024-04-17), Cabaletta Bio's share price is $15.13. Cabaletta Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.28. Hence, Cabaletta Bio's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Cabaletta Bio's Price-to-Operating-Cash-Flow or its related term are showing as below:

CABA's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.05
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Cabaletta Bio's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.33. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.28.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -4.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -16.40% per year.

During the past 7 years, Cabaletta Bio's highest 3-Year average Operating Cash Flow per Share Growth Rate was 18.60% per year. The lowest was -60.40% per year. And the median was -4.20% per year.

Cabaletta Bio Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Cabaletta Bio's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabaletta Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Cabaletta Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Cabaletta Bio's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cabaletta Bio Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Cabaletta Bio's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cabaletta Bio's Price-to-Operating-Cash-Flow falls into.

Cabaletta Bio Price-to-Operating-Cash-Flow Calculation

Cabaletta Bio's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	15.13	/	-1.283
	=

Cabaletta Bio's Share Price of today is $15.13.
Cabaletta Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.28.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Cabaletta Bio Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cabaletta Bio's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Cabaletta Bio (Cabaletta Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabaletta Bio Inc (NAS:CABA) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

CABA:Mexico

Address

2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104

Website

https://www.cabalettabio.com

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Executives

Gwendolyn Binder	officer: EVP, Science & Technology	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Shawn Tomasello	director	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Steven Nichtberger	director, officer: President & CEO	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Catherine Bollard	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Anup Marda	officer: Chief Financial Officer	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Mark Simon	director	C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arun Das	officer: Chief Business Officer	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Michael Gerard	officer: General Counsel	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Scott C. Brun	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Brian Daniels	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543